Insect Venom

PreclinicalSmall molecule

MMedical University of Graz

Insect Venom is one of 6 small molecule programs targeting Anaphylaxis. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AnaphylaxisActive, not recruiting

AnaphylaxisPreclinical

Active, not recruiting

Competition

Competitive Landscape

6 competitors in Anaphylaxis

#DrugCompanyPhaseTrials

Xolair

Roche

Phase 2

2 2

Calquence

AstraZeneca

Phase 2

1 3

Adrenaline

SSamson Clinical Operations Pty Ltd

Phase 2

1 4

Imbruvica

PPharmacyclics LLC.

Phase 2

1 5

Decadron

AAspen Global Incorporated

Phase 1

1 6

Insect Venom

MMedical University of Graz

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Anaphylaxis1 trial

The Effect of Antihypertensive Drugs on Severity of Anaphylaxis and Side-effects During Venom Immunotherapy

Completed·MMedical University of Graz··NCT04269629·1,425 enrolled

Bee Venom1 trial

Predominant Sensitizations to Single Bee Venom Allergens as a Risk Factor for Therapy Failure

Recruiting·MMedical University of Graz··NCT04259359·266 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Insect Venom. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Insect Venom compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Insect Venom. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Medical University of Graz company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: MMedical University of Graz

Insect Venom

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Anaphylaxis1 trial

Bee Venom1 trial

References

Drug Info

Quick Facts

Related News